Rivard Paul 4
4 · MyMD Pharmaceuticals, Inc. · Filed Apr 20, 2021
Insider Transaction Report
Form 4
Rivard Paul
EVP of Operations, GC
Transactions
- Award
Stock Option (Right to Buy)
2021-04-16+77,180→ 77,180 total(indirect: See footnote)Exercise: $2.59Exp: 2023-04-16→ Common Stock (77,180 underlying) - Award
Stock Option (Right to Buy)
2021-04-16+77,180→ 77,180 totalExercise: $2.59Exp: 2023-04-16→ Common Stock (77,180 underlying)
Footnotes (4)
- [F1]Received in exchange for a stock option to acquire 200,000 shares of common stock of a private company formerly known as "MyMD Pharmaceuticals, Inc." (the "Former Entity") at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the "Merger"). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.
- [F2]These options are fully vested and exercisable.
- [F3]Received in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share in connection with the Merger.
- [F4]These shares are jointly held by the reporting person and Jennifer Rivard as trustees for the Paul Rivard and Jennifer Rivard Revocable Living Trust.